Back

Safety profiling of CAR-T cells using an organotypic human tissue platform

Machado, A.; Birsen, G.; Rajnpreht, I.; Furtado Peter, I.; Colell, S.; Marzal, B.; Fredon, M.; Ziegler-Martin, K.; Martinez Bedoya, D.; Fumagalli, M.; Vimeux, L.; Davanture, S.; Melchiore, F.; Thomas, A.; Collet, M.; Fremand, X.; Burroni, B.; Laugel, B.; Lupo-Mansuet, A.; Prieto, M.; Damotte, D.; Le Doussal, J.-M.; Luu, M.; Dutoit, V.; Garnache-Ottou, F.; Guedan, S.; Migliorini, D.; Donnadieu, E.

2026-07-28 immunology
10.64898/2026.07.25.740527 bioRxiv
Show abstract

CAR-T-cell-associated on-target off-tumor (OTOT) toxicity represents a major safety concern, as recognition of target antigens on healthy tissues can trigger severe and potentially life-threatening complications. Predicting OTOT toxicity remains a challenge because current preclinical models fail to capture the complexity of native human tissues. Here, we developed a human organotypic tissue platform that enables functional assessment of CAR-T-cell activity in intact human tissues across organ-specific and inflammatory contexts. Using a panel of clinically relevant CAR-T-cell products with known OTOT toxicities, we demonstrate that the platform faithfully recapitulates clinically observed tissue-specific toxicity profiles. CAR-T cells targeting EGFR, HER2, and mesothelin induced inflammatory and cytotoxic responses in healthy human lung tissue, whereas CD19 CAR-T cells remained inactive. We further show that OTOT toxicity cannot be reliably predicted from antigen abundance alone but instead results from the integration of multiple target-dependent determinants, including CAR affinity, inflammatory context, antigen accessibility, and effector-cell dose. The platform also enables quantitative assessment of inflammatory and cytotoxic responses and supports evaluation of pharmacological and CAR design-based strategies to mitigate toxicity. Together, this work establishes the first human organotypic platform for functional modeling of CAR-T-cell-associated OTOT toxicity, providing a clinically relevant framework for preclinical safety evaluation and the rational development of safer engineered cell therapies. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=167 SRC="FIGDIR/small/740527v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@2b47e2org.highwire.dtl.DTLVardef@17c7ce2org.highwire.dtl.DTLVardef@1eaf9feorg.highwire.dtl.DTLVardef@1c295bb_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.